for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Shyndec Pharmaceutical Co Ltd

600420.SS

Latest Trade

8.55CNY

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

8.07

 - 

11.71

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
8.55
Open
--
Volume
--
3M AVG Volume
88.68
Today's High
--
Today's Low
--
52 Week High
11.71
52 Week Low
8.07
Shares Out (MIL)
1,026.94
Market Cap (MIL)
8,780.31
Forward P/E
--
Dividend (Yield %)
1.17

Latest Developments

More

Shanghai Shyndec Pharmaceutical's Board Elects Zhou Bin As Chairman

Shanghai Shyndec Pharmaceutical's 9-Mth Net Profit Down 0.4% Y/Y

Shanghai Shyndec Pharmaceutical's Prelim H1 Net Profit Down 9.3% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Shyndec Pharmaceutical Co Ltd

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Industry

Biotechnology & Drugs

Contact Info

No. 1320, Beijing West Road

+86.21.62510990

http://www.shyndec.com/

Executive Leadership

Bin Zhou

Chairman of the Board, General Manager

Bin Xiao

Chief Financial Officer

Dongsong Wei

Secretary of the Board, Deputy General Manager

Zhong Gong

Deputy General Manager

Zhiqun Yang

Deputy General Manager

Key Stats

Price To Earnings (TTM)
12.84
Price To Sales (TTM)
0.74
Price To Book (MRQ)
1.20
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
75.37
LT Debt To Equity (MRQ)
22.30
Return on Investment (TTM)
11.73
Return on Equity (TTM)
6.07

Latest News

Latest News

BRIEF-Shanghai Shyndec Pharma's preliminary 2016 net profit down 10.2 pct

* Says prelim 2016 net profit down 10.2 percent y/y at 474.6 million yuan ($69.05 million)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up